The primary purpose of early in vivo preclinical toxicity testing of drug candidates is to characterize potential adverse effects and provide a preliminary estimate of safety margins to determine if a compound is safe for human use, or to eliminate such molecules from further development.
In vivo preclinical toxicology studies are designed to assess the onset, severity, duration, dose dependency and irreversibility of toxic effects. At Creative Bioarray, in vivo toxicology services can range from acute (single dose) to chronic (multiple doses) dosing regimens. Several routes of exposure (e.g., oral, intravenous, intraperitoneal, intramuscular, topical, etc.) are available in a variety of species such as rodents, rabbits, and guinea pigs. A comprehensive toxicology evaluation can be obtained either through internal resources or through strategic partnerships with external suppliers. These evaluations include hematology, urinalysis, clinical chemistry, histopathology, bioanalysis and toxicokinetics.
Due to our state-of-the-art facilities and extensive experience in preclinical studies, we have the skill and expertise to accelerate the development of drug candidates from discovery to regulatory submission. We offer sophisticated and unique assessment methods including ultrasound, CT scanning, digital radiography, MRI, laser doppler, IVIS imaging, and Silhouette photography. In addition, we offer immunohistochemistry, ELISA, PCR, qPCR, and immunogenicity assays.
We have extensive experience in designing, implementing, evaluating and interpreting study results covering a wide range of endpoints, which means we can efficiently get the data in the format you need, so you can make timely and informed decisions about the mode-of-action, potential adverse effects and relevance to humans.